Haematologica

Article	Citations
The polymerase chain reaction, so simple, so clever: the discovery that made minimal residual disease come true	151
Bence Jones Island in Shepherd Bay, Nunavut: a little known tribute to the legendary physician and chemist’s “thé de voyage”	107
Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma	103
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection	97
Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients	85
A <i>Grammastola spatulata</i> mechanotoxin-4 (GsMTx4)-sensitive cation channel mediates increased cation permeability in human hereditary spherocytosis of multiple genetic etiologies	82
BCL2 inhibition in adult acute lymphoblastic leukemia: ready for primetime?	77
Intra-marrow delivery of human interleukin-6-loaded biodegradable microspheres promotes growth of patient-derived multiple myeloma cells in mice	75
Investigating the influence of germline <i>ATM</i> variants in chronic lymphocytic leukemia on cancer vulnerability	67
A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia	66
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation	63
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.	57
The first human acute myeloid leukemia genome ever fully sequenced	55
Venetoclax combined with escalating doses of homoharringtonine, low-dose cytarabine, and granulocyte colony-stimulating factor demonstrates feasibility and tolerability for remission induction in pedi	49
Acute myeloid leukemia at first relapse: approaching the precipice	48
Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia – the CONS	48
Soluble SLAMF7 is generated by alternative splicing in multiple myeloma cells	47
Recognition, prevention, and management of adverse events associated with asparaginase / pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel	46
An unusual case of thalassemia intermedia with inheritable complex repeats detected by single-molecule optical mapping	45
Impact of soluble thrombomodulin and activated protein C on dynamic hemostatic function in trauma: a focus on thrombin generation and clot lysis	45
Full <I>versus</i> prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis	44
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy	43
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma	42
The possible role of mutated endothelial cells in myeloproliferative neoplasms	41
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies	40

Asparaginase-associated hyperammonemia	40
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program	40
Specific inhibition of the transporter MRP4/ABCC4 affects multiple signaling pathways and thrombus formation in human platelets	40
Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade	40
Asparaginase dosing for acute lymphoblastic leukemia: more questions than answers	39
Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma	38
A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials	38
Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response	38
LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma	38
Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, metaanalysis, and call to action	37
Clonal hematopoiesis by DNMT3A mutations as a common finding in idiopathic splanchnic vein thrombosis	37
Acute lymphoblastic leukemia cells are able to infiltrate the brain subventricular zone stem cell niche and impair neurogenesis	36
“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms	36
Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies	36
CD47 expression in acute myeloid leukemia varies according to genotype	36
Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?	35
Potassium/sodium cation carriers robustly up-regulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cells	34
Prognostic relevance of variant allelic frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry	34
Running chromosome analysis in leukemia or not, upfront or later?	34
Prehistory of chronic lymphocytic leukemia: clues from the B-cell receptor	33
First-line MAPK inhibition in pediatric histiocytosis: are we ready?	31
SH2 domain-containing inositol 5-phosphatases support the survival of Burkitt lymphoma cells by promoting energy metabolism	31
Emergence of <i>TP53</i> mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine	31
New bullets in the fight against cancer	30
In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program	30
In-depth cytogenetic and immunohistochemical analysis in a real world cohort - reconsidering the role of primary and secondary aberrations in multiple myeloma	30
How we changed our approach to venous thromboembolism	30
Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia	30
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KM	29
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study	29
Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology	29
Kinetics matter: prognostic implications of early bone marrow assessment in acute myeloid leukemia	29
Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia	28
Acute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post cytotoxic therapy: a case report	28
Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study	28
Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate specific antigen membrane therapy	28
Monocyte response to SARS-CoV-2 protein ORF8 is associated with severe COVID-19 infection in patients with chronic lymphocytic leukemia	27
Epstein-Barr Virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments	27
The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease	27
Therapeutic targeting of endoplasmic reticulum stress in acute graft-<i>versus</i>-host disease	27
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial	27
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia	26
Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen	26
Treatment of lower-risk myelodysplastic syndromes	26
Advocating prudent D-dimer testing: constructive perspectives and comments on ‘How we manage a high D-dimer’	25
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia	25
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)	25
Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase	25
MAPK-kinase mutations and aortic lesions are associated with distribution of circulating monocytes in histiocytosis	24
Cytomegalovirus Triplex vaccine in pediatric hematopoietic stem cell transplant patients at high risk for cytomegalovirus complications: evaluation of vaccine safety, immunogenicity and impact on vire	24

Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of <i>PCM1::JAK2</i> with erythroblastic sarcoma: a case report and literature review	24
COVID-19 vaccine-induced adverse events predict immunogenicity among recipients of allogeneic hematopoietic stem cell transplantation	24
Safe platelet count for lumbar puncture: are we being overcautious?	24
Gut microbiome alterations at acute myeloid leukemia diagnosis are associated with muscle weakness and anorexia	24
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients	23
Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study	23
IgM monoclonal gammopathies of clinical significance: diagnosis and management	23
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients	23
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma	23
TIGIT: an immune checkpoint beyond T cells in chronic lymphocytic leukemia	23
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas	23
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies	22
Mutations in the <i>RACGAP1</i> gene cause autosomal recessive congenital dyserythropoietic anemia type III	22
Getting (T cells) ENGaged	22
Chronic lymphocytic leukemia and associated chronic lung diseases	22
<i>Ex vivo</i> venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia	22
STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of <i>BCL2</i> and <i>BCLXL</i> following glucocorticoid treatment	22
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients	22
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis	22
Mechanical unloading aggravates bone destruction and tumor expansion in myeloma	22
Landscape of immunoglobulin heavy chain γ gene class switch recombination in patients with adult T-cell leukemia–lymphoma	22
Identification of a clinicopathologic prognostic index for newly diagnosed large B-cell lymphoma patients treated with R-CHOP	21
LSD1/KDM1A and GFI1B repress endothelial fate and induce hematopoietic fate in induced pluripotent stem cell-derived hemogenic endotheliums	21
LNK/<i>SH2B3</i> as a novel driver in juvenile myelomonocytic leukemia	21
Aspirin is a life-saving drug for patients with acute myocardial infarction	21
Clonal evolution from B-cell acute lymphoblastic leukemia with <i>BCR::ABL1</i> multilineage involvement to acute myeloid leukemia after multiple anti-CD19 chimeric antigen receptor T-cell	21
Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden	21
COVID-19 thromboembolism is reduced in ambulatory, but not hospitalized patients, following COVID-19 vaccination Short title: COVID-19 thromboembolism	21
αβT- and B-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation in children with myelodysplastic syndromes	20
Teclistamab therapy for refractory type 1 cryoglobulinemia Teclistamab in type 1 cryoglobulinemia	20
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome	20
A sheep in wolf's clothing? Wild-type P53 disguises as mutant to promote leukemogenesis	20
CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?	20
Hemostatic and protein C pathway dysfunction in the pathogenesis of experimental cerebral malaria	20
Reply to the Comment on: “Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry”	20
Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Work	20
The International Prognostic Index: still relevant 30 years later	19
Genomic analysis of venous thrombosis in children with acute lymphoblastic leukemia from diverse ancestries	19
von Hippel- Lindau syndrome-related congenital polycythemia and response to belzutifan	19
An investigation of germline variants of <i>HAVCR2</i> in subcutaneous panniculitis-like T-cell lymphoma and related lesions in a North American population	19
Novel immunotherapies in multiple myeloma – chances and challenges	19
Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation	19
Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53-mutated B-cell prolymphocytic leukemia: a case report and literature review	19
More than a Lonca-shot: beating the odds in relapsed/refractory diffuse large B-cell lymphoma	19
A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome	19
Duality of Nrf2 in iron-overload cardiomyopathy	19
Biosimilars in rare diseases: a focus on paroxysmal nocturnal hemoglobinuria	18
A report from the Leukemia Electronic Abstraction of Records Network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment	18
LDHAL6B is a novel prognostic marker and promotes disease progression in multiple myeloma	18
Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma	18
The relative importance of platelet integrins in hemostasis, thrombosis and beyond	18
Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy	18
Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials	18
The effects of cardio-selective β blockade on diastolic dysfunction in children with sickle cell disease	17
Understanding pharmacological complement inhibition in paroxysmal nocturnal hemoglobinuria	17
Polytypic B cells, monotypic/monoclonal B-cell proliferations, and neoplastic T cells diverge from <i>TET2</i>-/<i>DNMT3A</i>-mutant clonal hematopoiesis in follicular helper T	17
Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapy.	17
Entities <i>versus</i> diseases: Myers <i>et al</i>. propose distinct aspects of adult T-cell lymphoma / leukemia.	17
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy	17
Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas	17
Introduction. Immunotherapy for childhood malignancies: the future is now	17
Type I interferons: leukemia's old foe in the limelight again	17
Association of <i>NUDT15</i> gene polymorphism with adverse reaction, treatment efficacy, and dose of 6-mercaptopurine in patients with acute lymphoblastic leukemia: a systematic review an	17
An extensive database analysis demonstrates significant increase in platelet quantity in unselected hospitalized patients following treatment with oseltamivir	17
Adenosine signaling inhibits erythropoiesis and promotes myeloid differentiation	17
Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase	16
Leon's helmet	16
Sex differences in progression of kidney disease in sickle cell disease	16
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma	16
Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding	16
Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia	16
Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma	16
Defibrotide improves COVID-19-related acute respiratory distress syndrome in myeloma patients after chimeric antigen receptor T-cell treatment without compromising virus-specific and anti-myeloma T-ce	16
Diagnostic challenges and proposed classification of myeloid neoplasms with overlapping features of thrombocytosis, ring sideroblasts and concurrent del(5q) and <i>SF3B1</i> mutations	16
Functional, biochemical, molecular and clinical characterization of antithrombin c.1157T>C (p.Ile386Thr), a recurrent Polish variant with a founder effect	16
Home time among older adults with acute myeloid leukemia by therapy intensity	16
Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma	16
Single-cell analysis of the T-cell receptor repertoire in untreated myeloma patients suggests potential myeloma-reactive CD8+ T-cells are shared between blood and marrow	16
Targeting Wnt signaling in acute myeloid leukemia stem cells	16
Umbilical cord blood T cells can be isolated and enriched by CD62L selection for use in 'off the shelf' chimeric antigen receptor T-cell therapies to widen transplant options	16

More on the pathogenesis of thrombotic thrombocytopenic purpura. Comment on “Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune	16
The E3 ligase TRIM31 regulates hematopoietic stem cell homeostasis and MLL-AF9 leukemia	15
Delving the depths of measurable residual disease negativity in acute myeloid leukemia	15
Modern, real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large B-cell lymphoma with or without double/triple-hit status in the United States	15
Teclistamab <i>versus</i> B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis	15
Aurora A kinase as a target for therapy in <i>TCF3-HLF</i> rearranged acute lymphoblastic leukemia	15
CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis	15
Dissecting CD47 expression in lymphoid neoplasms to inform precision immunotherapy with anti-CD47 phagocytic checkpoint blockade	15
Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade?	15
Somatic genetic alterations predict hematological progression in GATA2 deficiency	15
Clinical and molecular features of <i>CBL</i>-mutated juvenile myelomonocytic leukemia	14
MD-ALL: an integrative platform for molecular diagnosis of B-acute lymphoblastic leukemia	14
The double-edged sword of adenosine	14
Response to the Comment: “Advocating prudent D-dimer testing: constructive perspectives and comments on “How we manage a high D-dimer”	14
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome	14
Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia	14
A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopo	14
Factors associated with left ventricular hypertrophy in children with sickle cell disease: results from the DISPLACE study	14
m<sup>6</sup>A reader Ythdf3 protects hematopoietic stem cell integrity under stress by promoting the translation of <I>Foxm1</i> and <i>Asxl1</i> transcripts	14
Amyloidogenic light chains impair plasma cell survival	14
Syndromes predisposing to leukemia are a major cause of inherited cytopenias in children	14
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study	14
Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application	14
<i>BRCA1/2</i> mutations and <i>de novo</i> hematologic malignancies: true, true and not clearly related	14
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors	14
Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortali	14
Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism.	14
Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings	14
Systemic diffuse large B-cell lymphoma involving the central nervous system have high rates of defective antigen presentation and immune surveillance	13
Immunosuppression with post-transplant cyclophosphamide for allogeneic hematopoietic cell transplantation	13
Deep immunophenotypic dissection and clinical impact of T cells in the follicular lymphoma microenvironment	13
Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial	13
RNA helicase DHX15 exemplifies a unique dependency in acute leukemia	13
Do it once, but do it right	13
Artificial intelligence-based Myelodysplastic Syndromes Score, 2022 classifications, and the Molecular International Prognostic Scoring System: a perfect match	13
Ethnicity in systemic AL amyloidosis may impact risk stratification	13
Expanding treatment options by selectively targeting the cytokine storm with ruxolitinib in primary hemophagocytic lymphohistiocytosis	13
Enhancement of PRMT6 binding to a novel germline <i>GATA1</i> mutation associated with congenital anemia	13
Arkadia: a new player in hematopoietic stem and progenitor cell development	13
Evaluation of the <i>ATM</i> L2307F germline variant in 121 Italian pedigrees with familial myeloproliferative neoplasms	13
Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement	12
Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?	12
Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia	12
Phosphatase, Mg<sup>2+</sup>/Mn<sup>2+</sup> dependent 1B regulates the hematopoietic stem cells homeostasis via the Wnt/β-catenin signaling	12
Preventing central nervous system spread in diffuse large B-cell lymphoma – novel approaches needed	12
Depletion of the RNA binding protein QKI and circular RNA dysregulation in T-cell acute lymphoblastic leukemia	12
Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter	12
Mucosal-associated invariant T cells are functionally impaired in pediatric and young adult patients following allogeneic hematopoietic stem cell transplantation and their recovery correlates with cli	12
Treatment-related mutagenic processes in acute lymphoblastic leukemia	12
Detection of <I>ABL1</I> kinase domain mutations in therapy-naïve <I>BCR-ABL1</I>-positive acute lymphoblastic leukemia	12
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual di	12
Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A	12
Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia	12
Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis	12
Concurrent peripheral T-cell lymphoma and T-cell lymphoblastic leukemia/lymphoma with identical <i>STIL</i>::<i>TAL1</i> fusion events	12
Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes	12
Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant	12
<i>ASXL1</i> mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms	12
Hematopoietic cell transplants for acute leukemias	12
Acute myeloid leukemia with mast cell differentiation is characterized by interstitial mast cells, complex karyotype, <i>TP53</i> alterations and poor prognosis	12
B-cell precursor acute lymphoblastic leukemia elicits an interferon-α/βresponse in bone marrow-derived mesenchymal stroma	12
Immune reconstitution dynamics after unrelated allogeneic transplantation with post-transplant cyclophosphamide compared to classical immunosuppression with anti-thymocyte globulin: a prospective coho	12
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia	12
Sorting nexin 24 is required for α-granule biogenesis and cargo delivery in megakaryocytes	12
Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated with odronextamab	12
For older adults with hematologic malignancies, a comprehensive geriatric assessment matters	11
Hereditary anemia caused by multilocus inheritance of <i>PIEZO1</i>, <i>SLC4A1</i> and <i>ABCB6</i> mutations: a diagnostic and therapeutic challenge	11
Do older patients truly benefit from advances in myeloma care?	11
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde	11
MicroRNA and long non-coding RNA analysis in IgM monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis	11
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies	11
Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥ 60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): res	11
<i>FLT3-ITD</i> signals bad news for core binding factor acute myeloid leukemia unless trisomy 22 comes to the rescue	11
Clinical and molecular response of acute myeloid leukemia harboring non-canonical <i>FLT3</i> N676K driver mutations to contemporary FLT3 inhibitors	11
Nandrolone decanoate: new therapeutic option for telomeropathies?	11
Treatment of drug-induced immune thrombocytopenias	11
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse	11
Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm	11
Effects of corticosteroids in patients with sickle cell disease and acute complications: a systematic review and meta-analysis	11
Are clinical pharmacology studies still needed in childhood acute lymphoblastic leukemia?	11
How different are blood platelets from women or men, and young or elderly people?	11
Functional and multi-omics signatures of mitapivat efficacy upon activation of pyruvate kinase in red blood cells from patients with sickle cell disease	11
Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia	11
Intricacies of GATA-ca, continued	11
Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment	11
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE t	11
Evolution in treatment of acute promyelocytic leukemia: a major victory	11
Prevention, diagnosis and management of myeloproliferative neoplasms: an introduction to a review series	10
Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series	10
Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting	10
Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study	10
Diagnosis of immune thrombocytopenia, including secondary forms, and selection of second-line treatment	10
A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma	10
Bisecting GlcNAc expression by bone marrow stromal cells modulates TGF-β1-driven macrophage polarization in myeloid leukemias	10
Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity	10